Thomas Templeman - 01 Jul 2022 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Reporting relationship: Chief Technology Officer
Issuer ticker: CNTA
Reported as of: 01 Jul 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jul 2022, 18:15:36 UTC
Prior SEC filing: 03 Feb 2022
Next SEC filing: 23 Nov 2022
Source filing: View source filing
Reporting owner signature: /s/ Marella Thorell, attorney-in-fact

Key filing fact

Thomas Templeman filed Form 4 for Centessa Pharmaceuticals plc (CNTA) on 06 Jul 2022.

Key facts

This page summarizes Thomas Templeman's Form 4 filing for Centessa Pharmaceuticals plc (CNTA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 06 Jul 2022, 18:15.

Change

Previous filing in this sequence was filed on 03 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CNTA transaction

Ordinary Shares

Award

Transaction value: $0
Shares: +140,000
Change %: +56000%
Price: $0.000000
Shares after: 140,250
Date: 01 Jul 2022
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Footnote F2

The shares reported in this transaction represent Restricted Share Units ("RSUs") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in 10 equal quarterly instalments with the first such quarterly vesting being on September 30, 2022.